Proposed tariffs on Canadian pharmaceutical imports could have significant implications for the U.S. drug supply chain, potentially leading to increased costs and shortages of vital medications. According to a research letter, about $3 billion worth of U.S. pharmaceuticals rely on Canadian manufacturing, and the proposed 25% tariffs could potentially add $750 million in costs. Supply chain disruptions and the potential for shortages are major concerns. While the immediate impact may not be apparent, health care providers are advised to closely monitor the drugs they depend on and anticipate potential shifts in the market and supply chains. The study highlights that certain medications, including antibiotics, pain medications, and antidepressants, could face supply disruptions due to the tariffs. The authors emphasize the need for pharmaceuticals to be exempt from tariffs to avoid escalating healthcare costs and worsening disruptions in the U.S. supply.

Source: JAMA